George M. Milne Jr.

George M. Milne Jr. is a declared insider at 3 companies (board member); the most frequent names are Amylyx Pharmaceuticals, Inc., Aurinia Pharmaceuticals Inc. and Charles River Laboratories International, Inc. Over a trading history stretching from 7 May 2021 to 5 October 2026, the count stands at 12 filings.

Both buying and selling appear: 4 purchases worth €857k, against 2 sales worth €1.7M. On balance, insiders were net sellers of €878k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 1 share grant and 1 option exercise. So far in 2026, the count stands at no purchases and 1 sale.

The median purchase comes to €183k. On 1 out of 4 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 67% of cases; the median change was +7.9%. They describe history only and say nothing certain about the share price ahead.

Most recently, on 7 October 2026, the filings show an open-market sale worth €739k in Amylyx Pharmaceuticals, Inc. The last purchase on record was published on 5 September 2024, which is 773 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.